Use of Hormone Provides No Neuroprotection in Preemies, Says Study

High-dose erythropoietin treatment does not lower the risk of death or severe brain damage before 2 years of age in children who had been born at a very premature stage.

In extremely premature babies erythropoietin treatment may not provide neuroprotection, revealed study published in the Jan edition of the New England Journal of Medicine.

This multicenter study was led by Sandra E. Juul, professor of pediatrics and head, Division of Neonatology, at the University of Washington School of Medicine in Seattle. The researchers randomized more than 900 infants to receive either high-dose erythropoietin or a placebo severa; times a week from birth to 32 weeks corrected age, which is how old the baby would be if born on the due date.

Erythropoietin (EPO) - Facts and Mode of Action
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues (hypoxia), and stimulates red cell formation in bone marrow.

‘High-dose erythropoietin treatment does not lower the risk of death or severe brain damage before 2 years of age in children who had been born at a very premature stage. ’

There were no differences in severe side effects between the treatment and placebo groups. Juul said she was surprised and disappointed by the results.

"There was ample preclinical data to suggest that EPO would decrease neurologic damage that preterm infants suffer," she said.

However, she added, the project team does plan to follow the children in the study as they grow, because testing at 2 years of age may not reflect their later development.

Study: Single, High-dose Erythropoietin Given 2 Days Pre-op Reduces Need for Transfused Blood
In non-cardiac and cardiac surgical procedures, anemia increases operative mortality and morbidity.

The PENUT (Preterm EPO Neuroprotection Trial) examined the effect of the drug erythropoietin (e-rith-ro-PO-e-tin, “EPO” for short) on the brains of 940 babies born between 24 and 28 weeks. They are the tiniest of preemies – babies born before 37 weeks. Started in 2013, PENUT received $10 million from the National Institutes of Health to enroll and track these babies during their hospital stays and beyond, to 2 years of age. UW Medical Center’s team are coordinating the study across 29 hospitals in the United States.

The drug was administered to newborns within 24 hours of birth. The babies then received a total of 10 injections between birth and 32 weeks. Cognitive and neurological tests are then conducted at 2 years.

Outcomes of Erythropoietin Use for Heart Attack Patients Undergoing PCI Examined
Epoetin alfa is a product that stimulates red blood cell production.

Erythropoietin is a naturally occurring hormone made by the kidneys. It is involved in production of red blood cells, and is used to treat anemia. Erythropoietin is also found in the brain. Other studies have suggested it may help protect brain cells from injury by controlling immune responses and inflammation.

Source-Newswise

Understanding Brain Death
Interactive section of Medindia helps us in better understanding of Brain Death